Compared with the PBS control treatment, recombinant IL-22 treatment (1 month, twice weekly) reduced the infiltration of Ly6G+ cells in the epithelial cell lining and significantly reduced neutrophil elastase 2 levels in the lung homogenates of Mtb-infected T2DM mice (4.22 ±1.45 ng/ml vs. 2.18 ± 0.59 ng/ml, p<0.05; Fig 6G). This evidence concerns the gene IL22 and type 2 diabetes mellitus.